Exploration of the human melanoma cell-cycle pathway can lead to identification of new therapeutic targets. By gene set enrichment analysis, we identified the cell-cycle pathway and its member polo-like kinase 1 (Plk-1) to be significantly overexpressed in primary melanomas and in melanoma metastases. In vitro expression of Plk-1 was peaked at the G2/M phase of the cell cycle. Plk-1 knockdown/inhibition led to induction of apoptosis, which was caspase-3/8-dependent and p53-independent, and involved BID and Bcl-2 proteins. Comparative genomic hybridization/single-nucleotide polymorphism arrays showed no genetic alteration in the Plk-1 locus. Previous suggestions and significant enrichment of the mitogen-activated protein kinase (MAPK) signaling pathway pointed to potential regulation of Plk-1 by MAPK signaling. Inhibition of this pathway resulted in decreased Plk-1 expression as a consequence of G1 cell-cycle arrest rather than direct regulation of Plk-1. Inhibition of MAPK and Plk-1 had an additive effect on reduced cell viability. This study shows that in human melanoma, Plk-1 expression is dynamically regulated during the cell cycle, knockdown of Plk-1 leads to apoptotic cell death, and that a combination of Plk-1 and MAPK inhibition has an additive effect on melanoma cell viability. We conclude that combined inhibition of Plk-1 and MAPK could be a potentially attractive strategy in melanoma therapy.
INTRODUCTION
Skin cancers are the most common cancers worldwide (Lotze et al., 2001) . After basal cell and squamous cell carcinoma, melanoma is the third most common skin cancer in the general population and the most common in young adults aged 25-29 years (Linos et al., 2009) . At the localized stage, melanoma can be cured by surgery. However, at the metastatic stage, it becomes a devastating and incurable disease leading to patient's death within a few months to a year (Lotze et al., 2001) . Conventional therapies such as chemotherapy and radiotherapy have shown little success in the treatment of metastasizing melanoma (Garbe et al., 2010) . This necessitates the search for new therapeutic targets to combat melanoma particularly at the advanced stage.
Genetic analysis of melanoma has shown this tumor to be a heterogeneous cancer harboring frequent mutations in genes involved in intracellular signal transduction cascades regulating fundamental processes, such as cell cycle, cell proliferation, survival, and resistance to chemotherapy/radiotherapy (Kwong et al., 2007) . The most important signaling pathway in melanoma is the mitogen-activated protein kinase (MAPK) pathway, in which two of its members, namely NRAS or BRAF, harbor activating mutations in up to 80% of human melanomas in a mutually exclusive manner (Fecher et al., 2008) . It has also recently been shown both in preclinical and in clinical studies that targeting members of the MAPK signaling pathway could have a therapeutic potential for melanoma (Haass et al., 2008; Flaherty and Smalley, 2009 ).
Polo-like kinase 1 (Plk-1) is a mitotic serine/threonine kinase. In humans, four structurally related Plks have been identified , of which Plk-1 appears to be indispensable for cell-cycle progression and presumably for cancer cell proliferation (Barr et al., 2004) . The kinase activity of Plks is regulated at least in part, by the polo-boxes that are functionally important for both auto-inhibition and subcellular localization (Cheng et al., 2003) . Levels and activity of Plk-1 are low during the G1 and S phases of the cell cycle, increase during the G2 phase, peak during the M phase, and rapidly decline as the cell exits mitosis (Golsteyn et al., 1995; Whitfield et al., 2002) .
Plk-1 is mostly expressed in rapidly proliferating tissues, particularly in those with an unstable genome, such as cancer cells (Guan et al., 2005) . There is a substantial body of data linking Plk-1 to cancer. Plk-1 is highly expressed in many human tumors, such as breast, cervical, ovarian, thyroid, gastric, hepatocellular, pancreatic, colorectal, prostate cancer, and melanoma, as well as non-melanoma skin cancers (Takahashi et al., 2003; Gray et al., 2004; Weichert et al., 2004; Schmit et al., 2009a, b) . Interestingly, in some cancers including melanoma, the expression of Plk-1 could be clearly correlated with poor prognosis (Strebhardt et al., 2000; Weichert et al., 2004 Weichert et al., , 2005 He et al., 2009) . Constitutive overexpression of Plk-1 induces rapid cell cycling and confers an oncogenic transformed phenotype to NIH-3T3 fibroblasts (Smith et al., 1997) .
Importantly, depletion of Plk-1 in normal (non-cancer) cell lines does not arrest the cell cycle at least for the first few divisions (Guan et al., 2005; Schmit et al., 2009b) . Therefore, therapeutic approaches targeting Plk-1 may predominantly affect cancer cells, while sparing normal cells making it an attractive target in the treatment of cancer. Indeed, in vitro and in vivo preclinical studies have shown potential suitability of targeting Plk-1 in the treatment of different cancers (Degenhardt and Lampkin, 2010; Wäsch et al., 2010) .
In this study, using cDNA microarray technique and gene set enrichment analysis (GSEA) (Xu et al., 2008) , we identified the cell-cycle pathway to be enriched and its member Plk-1 to be strongly upregulated in human primary melanomas and in melanoma metastases as compared with melanocytic nevi. Comparative genomic hybridization and single-nucleotide polymorphism arrays showed no amplifications or deletions at the respective gene locus, therefore ruling out a genetic alteration. We demonstrate that in the absence of Plk-1, human melanoma cell lines including those from the NCI-60 panel undergo p53-independent apoptotic cell death. Furthermore, we show that the reduced levels of Plk-1 subsequent to MAPK signaling blockade are merely a consequence of G1 cell-cycle arrest rather than being a direct regulation by the MAPK signaling pathway. In addition, finally, a combination of MAPK inhibition and Plk-1 knockdown has an additive effect in suppressing the viability of human melanoma cell lines.
RESULTS
GSEA identifies the cell-cycle pathway and its member Plk-1 to be enriched and differentially expressed in primary melanomas and in melanoma metastases as compared with melanocytic nevi
We performed gene expression profiling on healthy skin, melanocytic nevi, primary melanomas, melanoma metastases, and human melanoma cell lines using Affymetrix U133A Oligonucleotide Microarray platform (Affymetrix, Santa Clara, CA). Using this strategy, we determined the expression of 22,283 genes. GSEA (http://www.broadinstitute. org/gsea) is a computational method that determines whether an a priori defined set of genes shows statistically significant, concordant differences between two biological states (Xu et al., 2008) . We obtained a list of genes most differentially expressed between primary melanomas, melanoma metastases, and melanocytic nevi ( Supplementary Table 1 online). In addition, by using GSEA and pathways from Biocarta (www.biocarta. com), GenMAPP (www.genmapp.org), and KEGG (www. genome.jp/kegg) databases, we could identify signaling pathways that were enriched in primary melanomas and in melanoma metastases as compared with melanocytic nevi ( Supplementary Table S2 online). Association of any of the 50 genes most overexpressed in primary melanomas and in melanoma metastases with the corresponding enriched pathways in these groups would indicate the importance of a gene. We observed the cell-cycle pathway to be the third most significantly enriched pathway in primary melanomas and in melanoma metastases as compared with melanocytic nevi (P ¼ 0.0008) after the MAPK pathway (P ¼ 0.0003) and the cyclin E destruction (fbw7) pathway (P ¼ 0.0001).
Searching the 50 most overexpressed genes of primary melanomas and metastases as compared with melanocytic nevi for members of the cell-cycle pathway resulted in identification of Plk-1 (the 37th most differentially expressed gene). Interestingly, other members of the Plk family, Plk-2, -3, and -4, were not present in this list and also showed no significant expression difference between melanocytic nevi and melanomas (data not shown).
The expression of Plk-1 is significantly higher in primary melanomas and melanoma metastases than in melanocytic nevi
The gene microarray data showed relatively low expression of Plk-1 melanocytic nevi. The expression was increased in primary melanomas and was highest in melanoma metastases (Figure 1a , Po0.001, analysis of variance with Tukey's post-test). Using an independent set of samples and quantitative real-time PCR, a similar pattern of expression was observed (Figure 1b , Po0.001, analysis of variance with Tukey's post-test).
The expression of Plk-1 is dynamically regulated in human melanoma cell lines, and its peak expression is restricted to the G2/M phase of the human melanoma cell cycle.
We used three well-established human melanoma cell lines, M14 (NCI-60 panel of human cancer cell lines, http:// dtp.nci.nih.gov/docs/misc/common_files/cell_list.html), WM-115, (Figure 2a ). Interestingly, double staining of cells for Plk-1 and propidium iodide (PI) showed Plk-1positive cells to be tetraploid corresponding to cells present in the G2/M phase of the cell cycle ( Figure 2b ). Phosphorylation at Ser10, Ser28, and Thr11 of histone H3 is tightly correlated with chromosome condensation during mitosis (Goto et al., 1999) . Human melanoma cells expressing phospho-histone H3 were all Plk-1 positive (Figure 2c ), further confirming our observation that Plk-1 expression is mainly in the G2/M phase of the cell cycle. To study the role of Plk-1 in human melanoma cell biology, small-interfering RNA (siRNA)-based silencing was used. Specific targeting of Plk-1 with commercially available Plk-1 siRNA and by transient transfection with pSuper vector expressing self-designed Plk-1 siRNA led to significant reduction in the Plk-1 mRNA (data not shown) and protein in comparison with control siRNA-treated cells as shown by western blot (WB) analysis ( Figure 2d ). We observed significant reduction in the viability of M14 and WM-115 human melanoma cell lines as Plk-1 was silenced (Figure 2e ).
This phenomenon was observed in 11 other human melanoma cell lines including those from the NCI-60 panel all expressing the Plk-1 protein (SK-MEL-2, SK-MEL-5, SK-MEL-28, WM-35, LOX-IMVI, A375, HT-144, WM-983 A, MEWO, UACC-62, and UACC-257, Supplementary Figure 1 online). Interestingly, specific inhibition of Plk-1 using the commercially available inhibitor BI 2536 led to a dose-and time-dependent decrease in human melanoma cell viability ( Figure 2f ). There was a pronounced and significant fragmentation of nuclei upon knockdown of Plk-1, a phenomenon described to be associated with apoptosis or mitotic catastrophe (Eom et al., 2005) (Figure 3a and b). Decreased cell viability was accompanied by an increase in apoptosis as shown by annexin V assay ( Figure 3c ). Indeed, we also observed cleavage of caspase-3 and -8 upon Plk-1 knockdown as shown by WB analysis in Figure 3d . Cleaved caspase-3 is a hallmark of apoptosis, and caspase-8 cleavage points to the activation of the extrinsic pathway of apoptosis. Interestingly, concomitant use of Plk-1 siRNA and pancaspase inhibitor (Apo-Block) led to complete rescue of cells from apoptosis ( Figure 3c ). As caspase-8 cleavage was seen upon Plk-1 silencing, it was important to see whether caspase-8 inhibition could also cause a complete rescue from apoptosis. To test this possibility, cells were concomitantly treated with Plk-1 siRNA and a specific caspase-8 inhibitor (Z-IETD-FMK). The rescue was partial, suggesting the involvement of both extrinsic and intrinsic branches of apoptosis ( Figure 3c ). The p53 pathway has previously been shown to be involved in Plk-1 depletion-induced apoptosis (Liu and Erikson, 2003) . To see whether p53 is involved in the induction of apoptosis after depletion of Plk-1 in human melanoma, melanoma cell lines M14 (harboring heterozygous p53-inactivating mutation (Ikediobi et al., 2006) ) and WM-115 (p53 wild type) were transfected with either Plk-1 or control-scrambled siRNAs, and protein was extracted at different time points and subjected to WB analysis for p53 protein. There was no change in the expression of the p53 protein or its downstream target p21 after Plk-1 knockdown as compared with the control group at 12, 24, and 48 hours post-siRNA treatment (Figure 4a ). To further rule out the involvement of p53 in Plk-1 knockdown-mediated apoptosis, p53 and Plk-1 were simultaneously silenced. Despite a significant reduction in the amount of p53 protein, cells could not be rescued from the Plk-1 knockdown-mediated induction of apoptosis ( Figure 4b ). When screening for the involvement of other potential candidates, we identified a decrease in uncleaved BID and Bcl-2 (known as the inhibitor of apoptosis) at 48 hours after Plk-1 silencing (Figure 4c ) when caspase-3 and -8 cleavage was also observed (Figure 3d ). There was no change in the protein levels of apoptosisinducing factor, Apaf-1, and caspase-9 belonging to the intrinsic pathway of apoptosis (data not shown). Mitochondrial cytochrome c release was observed at a later time point (72 hours after Plk-1 siRNA transfection, Supplementary  Figure 2 online). These results argue for the induction of both intrinsic and extrinsic pathways of apoptosis after Plk-1 knockdown in melanoma cell lines.
MAPK inhibition induces cell-cycle arrest at the G1 phase and decreased Plk-1 protein levels MAPK is the most important signaling pathway in human melanoma because of frequent mutations leading to constitutive activation of the pathway (Fecher et al., 2008) . In GSEA, this pathway was also significantly enriched in human primary melanomas and in melanoma metastases than in melanocytic nevi (P ¼ 0.0003). It has recently also been suggested that the MAPK signaling pathway might be regulating the expression of Plk-1 in chronic myeloid leukemia (Gleixner et al., 2010) . To see whether inhibition of this pathway has an impact on the expression of Plk-1 in human melanoma, we used specific inhibitors of mitogenactivated protein kinase kinase (MEK) 1/2 (PD98059), c-Jun N-terminal kinase (JNK) (JNK inhibitor II), p38 MAPK (SB203580), and the multikinase inhibitor (sorafenib). Treatment of human melanoma cell lines WM-115 and M14 with these inhibitors was accompanied with significant reduction of Plk-1 protein levels (Figure 5a ). This phenomenon was accompanied by induction of apoptosis ( Figure 5b ). The MEK 1/2 inhibitor PD98059 inhibited Plk-1 expression in a dose-and time-dependent manner (data not shown).
It is known that MAPK inhibition results in cell-cycle arrest at the G1 phase of the cell cycle (Koo et al., 2002) . Therefore, decreased expression of Plk-1 could be a consequence of cell-cycle arrest rather than being a direct regulation by the MAPK signaling pathways. Indeed, treatment of M14 and WM-115 human melanoma cells with PD98059 led to cellcycle arrest at the G1 phase ( Figure 6a ). Continuous treatment with PD98059 significantly reduced the Plk-1 protein level (Figure 6b ), and discontinuation of this treatment led to re-expression of the Plk-1 protein (Figure 6b ).
As in PD98059-treated cells, thymidine block also led to a cell-cycle arrest at the G1 phase (Figure 2a ). Importantly, the expression of the MAPK target protein-phospho-extracellular signal-regulated kinase was not changed in human melanoma cell lines WM-115 and M14 after thymidine block, in contrast to treatment with PD98059 that substantially decreased its expression ( Figure 6c ). Both thymidine block and PD98059 treatment resulted in decreased expression of the Plk-1 protein (Figure 6c ). These results further argue that decreased expression of Plk-1 after MAPK inhibition is a consequence of cell-cycle arrest rather than being a direct regulation by the MAPK signaling pathway.
Simultaneous inhibition of MAPK and Plk-1 shows an additive effect on reduced viability
As demonstrated above, inhibition of the MAPK signaling pathway induces G1 phase cell-cycle arrest; however, Plk-1 knockdown results in a cell-cycle arrest at the G2 phase. Targeting cells at both the G1 and G2 phase of the cell cycle should theoretically result in a potentiation of either single treatment.
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DISCUSSION
Gene expression profiling is the measurement of the expression of thousands of genes at once to create a global picture of cellular function. This technique has shown to be of potential use for the identification of target genes in cancer for diagnostic, prognostic, and therapeutic purposes (Kwong et al., 2007; Hartman et al., 2010; Subramanian and Simon, 2010) .
In this study, we measured the expression of 422,000 genes in human primary and metastatic melanomas, as well as in human melanocytic nevi. By GSEA, we were able to obtain a list of the 50 most overexpressed genes in primary melanomas and in melanoma metastases as compared with melanocytic nevi. By integrating the results obtained from GSEA with pathway enrichment analysis, we could identify Plk-1 to be the only member of the enriched cell-cycle pathway present in the list of the 50 most overexpressed genes. Analysis of gene expression values of Plk-1 in melanocytic nevi, primary melanomas, and melanoma metastases demonstrated a significant difference with an increasing trend toward human melanoma metastases. This could be confirmed by using an independent set of samples and quantitative real-time PCR for Plk-1 mRNA.
As expected, the higher Plk-1 expression in our gene microarray data correlated with poorer prognosis (although not significant, data not shown). It has also been previously shown that primary melanomas with developed metastases express Plk-1 at markedly elevated levels compared with melanomas without metastases, suggesting Plk-1 expression to be a reliable marker to identify patients at high risk for metastases (Kneisel et al., 2002) .
Using comparative genomic hybridization analysis and single-nucleotide polymorphism arrays (data not shown) in our samples, we found no genetic alterations at the gene locus 16p12.1 where Plk-1 resides. There have also been no reports in the literature about possible genetic alterations affecting Plk-1 expression at this locus. Therefore, we postulate that the reason behind the increased expression of Plk-1 in primary melanomas and in melanoma metastases is the increased proliferation rate of melanoma cells as compared with cells in nevi, leading to increased Plk-1 expression rather than direct genetic alterations in the Plk-1 locus.
Consistently, the expression of Plk-1 was dynamically regulated during the human melanoma cell cycle as in earlier reports. The peak expression value was observed during the G2/M phase of the cell cycle. This has also been shown to be the case in other cancer cells (Archambault and Glover, 2009 available Plk-1 siRNA in human melanoma cell lines M14, HT-144, and WM-115 led to cell-cycle arrest at the G2/M phase of the cell cycle and decreased viability. This was followed by nuclear fragmentation and caspase-3 and -8 cleavage. Interestingly, specific caspase-8 or pan-caspase inhibition by small-molecule inhibitors or specific caspase-3 or/and -8 siRNA-based silencing (data not shown) was able to partially to completely rescue cells from programmed cell death or apoptosis.
In 14 human melanoma cell lines tested, including those from the NCI-60 panel, all were sensitive to Plk-1 knockdown. The degree of sensitivity did not correlate with the origin of cells (primaries or metastatic melanoma, radial or vertical growth phase) or mutational status (including BRAF, NRAS, p53, PTEN, CDK4, CDKN2A, NF1, and ATM). It has been previously shown that normal human epidermal melanocytes are resistant to Plk-1 knockdown or inhibition (Schmit et al., 2009b) . Interestingly, in our hands, hTERT/ CDK4 (R24C) /p53 DD -immortalized human melanocytes were more resistant to Plk-1 inhibition by BI 2536 as compared with BRAF V600E -transformed cells (hTERT/CDK4 (R24C) /p53 DD / BRAF V600E representing more the human melanoma cell lines and needing a five times greater concentration of the inhibitor to be growth arrested ( Supplementary Figure 3 online) .
It has been previously shown in other cancer cell lines that lack of Plk-1 induces p53-dependent apoptosis (Liu and Erikson, 2003) . In our study, we observed no change in the expression of p53 in the absence of Plk-1. In contrast, in both human melanoma cell lines M14 (harboring a heterozygous p53-inactivating mutation) and WM-115 (wild-type p53), the expression of the anti-apoptotic protein Bcl-2 was substantially decreased. Concomitant knockdown of p53 with Plk-1 could not rescue the cells from Plk-1-mediated induction of apoptosis arguing against an involvement of the p53 pathway.
In the absence of Plk-1, cells underwent apoptosis with caspase-3 and -8 cleavage. Interestingly, specific caspase-8 or pan-caspase inhibition partially to completely rescued the cells. Cleavage of caspase-3 and -8 together with a decrease in the Bcl-2 protein level and cytochrome c release argues for the induction of both extrinsic and intrinsic pathways of apoptosis.
Not surprisingly, the MAPK signaling pathway was the second-most enriched pathway in primary melanomas and in melanoma metastases (as compared with melanocytic nevi) in our samples. It has recently also been suggested that the MAPK signaling pathway might regulate expression of Plk-1 expression in some cancer cell lines, such as chronic myeloid leukemia (Gleixner et al., 2010) . Interestingly, inhibition of MAP kinases MEK, JNK, p38, and multikinases (BRAF, CRAF, VEGFP by sorafenib) in WM-115 and M14 human melanoma cell lines led to either significant reduction or complete inhibition of the Plk-1 protein expression. Inhibitors of MAPK are also known to induce a cell-cycle arrest at the G1/S phase (Pumiglia and Decker, 1997; Lee et al., 2002) . Indeed, the MEK 1/2 inhibitor PD98059 induced a G1/S arrest in both human melanoma cell lines tested. The fact that thymidine block of cells at the G1 phase, where the MAPK signaling pathway is known not to be affected, had a similar effect on Plk-1 expression (Figure 2a ). This inhibition of Plk-1 expression by MAPK inhibitors might be rather the consequence of a G1/S phase cell-cycle arrest than direct regulation of Plk-1 expression. Indeed, downregulation of Plk-1 expression and G1 phase cell-cycle arrest upon thymidine block happens in the presence of active MAPK signaling pathway as demonstrated by the expression of phospho-p44/42 extracellular signal-regulated kinase 1/2. Continuous treatment of human melanoma cell lines WM-115 and M14 with MEK 1/2 inhibitor resulted in a significant decrease in Plk-1 protein levels; however, removal of MEK 1/2 inhibition resulted in a time-dependent re-expression of the Plk-1 protein.
Inhibitors of the MAP signaling pathway have recently been shown to have therapeutic effects in various cancers, including melanoma (Bollag et al., 2010; Flaherty et al., 2010a, b; Smalley, 2010) . These responses seem to be rapid but short lasting; therefore, combination strategies targeting members of other pathways such as cell cycle might open new therapeutic possibilities. Interestingly, combination of MAPK inhibition (G1 arrest) and Plk-1 knockdown (G2 arrest) had a significant additive effect on decreased viability of human melanoma cell lines.
Several small-molecule inhibitors of Plk-1 are currently in pre-clinical and early clinical trials for the treatment of various malignancies (Chopra et al., 2010; Degenhardt and Lampkin, 2010; Hofheinz et al., 2010) . On the basis of our data, it would be worth trying these inhibitors in melanoma patients keeping in mind that these inhibitors are shown not to have any effect on normal melanocytes and also to spare other normal non-cancerous cells (Schmit et al., 2009b) .
Finally, we conclude that combination of MAPK and Plk-1 inhibition could be a potentially attractive therapeutic strategy in melanoma.
MATERIALS AND METHODS

Cell lines, tissues, and reagents
Human melanoma cell lines WM-115 and HT-144 were obtained from American Type Culture Collection (Manassas, VA). The M14 cell line was from DCTD Tumor Repository (National Cancer Institute, Frederick, MD). Cells were cultured in RPMI 1640, supplemented with 10% heat-inactivated fetal calf serum, and 2 mM L-glutamine (all from Invitrogen, Carlsbad, CA) and hereafter referred to as culture medium. After seeding from cryopreserved stock, cells were passaged at least 2-3 times before experiments.
Propidium iodide (Sigma-Aldrich, Vienna, Austria), thymidine (Sigma-Aldrich), MEK 1 inhibitor PD98059, JNK inhibitor II, p38 inhibitor SB203580 (all from Merck KGaA, Darmstadt, Germany), as well as BI 2536 and multikinase inhibitor sorafenib (both from Selleck Chemicals LLC, Houston, TX) were used in this study.
RNA isolation, gene expression profiling, and quantitative real-time PCR analysis
Total RNA was isolated from monolayer cell cultures and cryopreserved tissues using TriReagent (Sigma, St Louis, MO) according to the manufacturer's instructions.
Tissue sampling and gene expression profiling were performed using Affymetrix U133A microarray platform as described previously (Xu et al., 2008) . Tissue samples contained normal skin (n ¼ 8), melanocytic nevi (n ¼ 9), human primary melanoma (n ¼ 31), and melanoma metastases (n ¼ 52). Institutional approval or patient consent was not necessary. Microarray experiments were conducted according to standard protocols for Affymetrix Genome U133A arrays. In brief, 1 ìg of total RNA was used to synthesize cDNA and biotinylated cRNA using the GeneChip expression 3-amplification reagent kits from Affymetrix. cRNA hybridization and scanning of the array were performed according to the manufacturer's protocols.
Gene set and pathway enrichment analyses have been performed as described previously (Xu et al., 2008) . The data have been deposited in the National Center for Biotechnology Information GEO (Clark et al., 2000) and are accessible through GEO Series accession no. GSE8401.
For RT-PCR study, independent sets of 6 melanocytic nevi, 12 primary melanomas, and 12 metastatic melanoma tissues were used. Reverse transcription was performed by SuperScript II reverse transcriptase using random hexamer and oligo-dT primers (all from Invitrogen). Plk-1, b-actin cDNAs, or 18S rRNA were amplified using primer/probe sets no. Hs00153444, no. Hs99999903-m1, and no. Hs99999901-s1, respectively, from Applied Biosystems (Foster City, CA). Reactions were performed in an AbiPrism 7700 DNA amplifier under the following conditions: initial heating at 501C for 2 minutes and 951C for 10 minutes, followed by 40 cycles consisting of a denaturation step (901C, 15 seconds) and an annealing/elongation step (601C, 1 minutes). Each sample was assayed in duplicate. Negative controls represented full PCR reaction mixtures with cDNA substituted by ddH 2 O. The readout for each reaction was cycle of threshold (Ct), i.e., the cycle number in which the fluorescent signal became higher than a pre-defined threshold.
Levels of Plk-1 mRNA in tumor tissues were expressed quantitatively as copy number of Plk-1 mRNA per 1,000 copies of b-actin mRNA. Quantitation was performed using calibration curves created using reference plasmids, which represented Plk-1 or b-actin cDNA (GeneBank accession numbers NM_005030 and NM_001101, respectively) cloned into the commercial pGEM-T Easy plasmid (Stratagene, La Jolla, CA).
In all other experiments, levels of Plk-1 mRNA were expressed semi-quantitatively using the DDCt method and 18S rRNA as a reference gene, according to the formula: 2 ÀDDCt ¼ 2 ÀððCt PlkÀ1 sampleÀCt 18S sampleÞÀðCt PlkÀ1 reference sampleÀCt 18S reference sampleÞÞ
Plk-1 detection in combination with cell-cycle analysis
For intracellular Plk-1 staining, melanoma cells were trypsinized, washed, fixed with 70% ethanol (1 hour on ice), permeabilized with 0.05% Tween (VWR International, Vienna, Austria) in phosphatebuffered saline (PBS) (Invitrogen), and incubated for 30 minutes at room temperature with either mouse anti-human Plk-1 mAb (ab 17057, Abcam plc, Cambridge, UK) or a control IgG1 (Immunotech, Marseille, France), both at 2.5 mg ml. Subsequently, cells were washed and incubated with FITC-labeled goat anti-mouse IgG F(ab 0 ) 2 fragments (Immunotech) at a 1:300 dilution, whereafter again washed.
To simultaneously perform the analysis of Plk-1 expression and cell-cycle analysis, cells were additionally incubated in a DNA staining buffer (10 mg ml PI and 250 mg ml RNAse A in PBS; 10 minutes at 371C). Cells were analyzed using a FACScan flow cytometer and CellQuest software (both from BD Biosciences, Vienna, Austria). Cells with different DNA content were gated separately according to PI staining, and Plk-1 signal (expressed as mean fluorescence intensity) was analyzed in the gated sub-populations after subtraction of background mean fluorescence intensity obtained from isotype control staining.
In some experiments, cells were stained with the mAb against Plk-1 and a polyclonal rabbit antibody against human phosphohistone H3 [pS 10 ] (Invitrogen) to identify mitotic cells. The two antibodies were visualized, respectively, by a phycoerythrinelabeled anti-mouse Ab (Jackson Immunoresearch, West Grove, PA) and an Alexa Fluor 488-labeled goat anti-rabbit Ab (Invitrogen). siRNA transfection, cell-cycle analysis, and MTT assay Transfection with validated Plk-1 (s448, Ambion, Austin, TX), p53 (sc-44218, Santa Cruz Biotechnology, Santa Cruz, CA), and negative control (AM4637, Ambion) siRNAs was performed using Lipofectamine 2000 transfection reagent (Invitrogen) according to the manufacturer's instructions.
Cell-cycle analysis was performed as described elsewhere (Haass et al., 2008) . In brief, on specific time points, cells were collected, resuspended in PBS (Invitrogen), and ice-cold 70% ethanol (Sigma-Aldrich) was added dropwise while mildly vortexing. After removing ethanol, cells were washed with 0.05% Tween-20 (Sigma-Aldrich) in PBS and then resuspended in DNA staining buffer (PBS/PI 10 mg ml/ RNase A 250 mg ml (Sigma-Aldrich). After 15 minutes incubation at 371C, PI signal was acquired in FL-2 or FL-3 channel of a flow cytometer using a linear scale (FACScan, BD Biosciences). Hypodiploid (necrotic/apoptotic), diploid (G1/G0), and tetraploid (G2/M) cells were quantified using CellQuest software (BD Biosciences).
For confocal laser scanning microscopy (Axiovert 200M; Carl Zeiss MicroImaging GmbH, Jena, Germany) analysis of cell nucleus after Plk-1 siRNA treatment, the Propidium Iodide Nucleic Acid Stain (cat. no. P-3566) protocol from Molecular Probes (Carlsbad, CA) was used.
Standard MTT assay was performed in 96-well plates as described previously (Dabrowska-Iwanicka et al., 2002) . The viability was measured using following formula:
Relative viability ¼½ðexperimental absorbance À background absorbanceÞ= ðabsorbance of untreated controls À background absorbanceÞÂ100%
Annexin V and caspase inhibition assays
For annexin V-based apoptosis detection assay, human melanoma cell lines were collected at desired time points after Plk-1 siRNA transfection or drug treatment. After washing in PBS (Invitrogen) cells were resuspended in 1 Â Binding buffer (BD Biosciences), and annexin V-FITC (BD Biosciences) and PI were added according to the manufacturer's protocols (BD Biosciences). After 15 minutes incubation at room temperature, cells were acquired by flow cytometry. All early apoptotic cells (annexin V positive) and necrotic/late apoptotic cells (annexin V positive, PI positive), as well as living cells (double negative) were detected by FACScan and subsequently analyzed by CellQuest software (BD Biosciences). For caspase inhibition assay, specific caspase-8 inhibitor, Z-IETD-FMK and pan-caspase inhibitor Apo-Block (both from BD Biosciences) were added to cell cultures 1 hour before Plk-1 silencing. DMSO-treated cells served as negative controls. Annexin V staining was performed at desired time points.
WB analysis
For WB analysis, human melanoma cells were washed with cold PBS (Invitrogen), lysed by treatment with radio immunoprecipitation assay buffer (50 mM Tris base (Merck Chemicals, Darmstadt, www.jidonline.org 1893
